Applied Molecular Transport Appoints Douglas Rich as Chief Technical Officer
Applied Molecular Transport Inc. (Nasdaq: AMTI) has appointed Douglas Rich as Chief Technical Officer, aiming to enhance GMP manufacturing and formulation development. He brings over 26 years of biopharma experience, with previous roles at UNITY Biotechnology and Amgen. This leadership change comes as the company advances its pipeline, initiating two Phase 2 trials for oral AMT-101 targeting pouchitis and rheumatoid arthritis. CEO Tahir Mahmood emphasizes Rich's expertise as key to AMT's growth strategy and ongoing clinical progress.
- Douglas Rich's appointment brings over 26 years of biopharma experience.
- Initiated two Phase 2 trials for oral AMT-101, indicating clinical progress.
- No specific financial metrics or timelines provided for new initiatives.
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership responsibilities for all process development, manufacturing, CMC and formulation activities, including quality and supply chain responsibilities. He will become a member of the AMT Executive Team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D.
“We continue to recognize the criticality of furthering our internal GMP manufacturing and formulation development for the company’s long-term success,” stated Tahir Mahmood, Ph.D. “Doug’s significant experience in technical operations and quality, and track record of building and leading high caliber teams, will serve as foundational components of our growth strategy. Last month, we initiated our second and third Phase 2 trials for oral AMT-101, FILLMORE for patients with pouchitis and CASTRO with oral AMT-101 in combination with approved anti-TNFα therapy for patients with rheumatoid arthritis. With continued progress in the clinic and across the business, I look forward to Doug’s important contributions as we advance our promising pipeline of novel, oral biologic medicines.”
With more than 26 years of experience in the biopharma industry, Mr. Rich brings deep operations and quality experience across the entire product lifecycle. He has served in leadership roles responsible for the development and commercialization of both biopharmaceuticals and small molecules. Mr. Rich most recently served as Senior Vice President, Operations at UNITY Biotechnology where he led Technical Operations, Quality, Supply Chain, and Portfolio/Project/Alliance Management. Prior to UNITY, he was Senior Vice President, Operations at Kythera Biopharmaceuticals, acquired by Allergan plc. Prior to Kythera, he was Vice President, Quality at Boehringer-Ingelheim where he worked in both the Biopharmaceutical and Prescription Medicine Business Units. Earlier in his career, Mr. Rich also spent over 18 years at Amgen, in various roles within Operations including Global Operations Strategy, Manufacturing, Quality Control, and Site Quality Head.
“I am extremely excited about joining the company at such an important time,” said Douglas Rich, chief technical officer of AMT. “It is critical to continue to build on the vision propelled by our technology platform and internal GMP manufacturing, product formulation and other technical capabilities to expand and advance our deep pipeline of promising oral biologic products.”
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or AMT’s future plans, strategy and performance. Such statements include, but are not limited to, the potential of, and expectations regarding AMT’s technology platform and AMT-101, statements regarding AMT’s Phase 2 clinical trials for AMT-101 including the timing of such trials and the dosing related to such trials, AMT’s ability to leverage its technology to expand its pipeline and Mr. Doug Rich’s potential contributions to AMT. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including those more fully described under the section entitled “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
Who is Douglas Rich and what is his role at AMTI?
What are the Phase 2 trials mentioned in the press release?
How does Douglas Rich's experience benefit AMTI?
What is the significance of internal GMP manufacturing for AMTI?
What should investors know about AMTI's clinical trials?
